Nikolaos-Renatos Tziolos

Dr. Nikolaos-Renatos Tziolos

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2023 in Microorganisms
Verified
Journal Article
Open access
PDF file
NTNikolaos-Renatos Tziolos
Nikolaos-Renatos Tziolos
PIPetros Ioannou
Petros Ioannou
SBStella Baliou
Stella Baliou
DKDiamantis P Kofteridis
Diamantis P Kofteridis
Long COVID-19 is a recognized entity that affects millions of people worldwide. Its broad clinical symptoms include thrombotic events, brain fog, myocarditis, shortness of breath, fatigue, muscle pains, and others. Due to the binding of the virus with ACE-2 receptors, expressed in many organs, it can potentially affect any system; however, it most often affects the cardiovascular, central nervous, respiratory, and immune systems. Age, high body mass index, female sex, previous hospitalization, and smoking are some of its risk factors. Despite great efforts to define its pathophysiology, gaps remain to be explained. The main mechanisms described in the literature involve viral persistence, hypercoagulopathy, immune dysregulation, autoimmunity, hyperinflammation, or a combination of these. The exact mechanisms may differ from system to system, but some share the same pathways. This review aims to describe the most prevalent pathophysiological pathways explaining this syndrome.

1 June 2016 in Clinical Microbiology and Infection
Verified
Journal Article
Open access
EGEvangelos J Giamarellos-Bourboulis
Evangelos J Giamarellos-Bourboulis
NTNikolaos-Renatos Tziolos
Nikolaos-Renatos Tziolos
CRC. Routsi
C. Routsi
CKC. Katsenos
C. Katsenos
ITI. Tsangaris
I. Tsangaris
AAA. Armaganidis
A. Armaganidis
The emergence of infections by multidrug-resistant (MDR) Gram-negative bacteria, which is accompanied by considerable mortality due to inappropriate therapy, led to the investigation of whether adjunctive treatment with one polyclonal IgM-enriched immunoglobulin preparation (IgGAM) would improve outcomes. One hundred patients in Greece with microbiologically confirmed severe infections by MDR Gram-negative bacteria acquired after admission to the Intensive Care Unit and treated with IgGAM were retrospectively analysed from a large prospective multicentre cohort. A similar number of patient comparators well-matched for stage of sepsis, source of infection, appropriateness of antimicrobials and co-morbidities coming from the same cohort were selected. All-cause 28-day mortality was the primary end point; mortality by extensively drug-resistant (XDR) pathogens and time to breakthrough bacteraemia were the secondary end points. Fifty-eight of the comparators and 39 of the IgGAM-treated cases died by day 28 (p 0.011). The OR for death under IgGAM treatment was 0.46 (95% CI 0.26-0.85). Stepwise regression analysis revealed that IgGAM was associated with favourable outcome whereas acute coagulopathy, cardiovascular failure, chronic obstructive pulmonary disease and chronic renal disease were associated with unfavourable outcome. Thirty-nine of 62 comparators (62.9%) were infected by XDR Gram-negative bacteria and died by day 28 compared with 25 of 65 cases treated with IgGAM (38.5%) (p 0.008). Median times to breakthrough bacteraemia were 4 days and 10 days, respectively (p <0.0001). Results favour the use of IgGAM as an adjunct to antimicrobial treatment for the management of septic shock caused by MDR Gram-negative bacteria. A prospective randomized trial is warranted.

6 May 2024 in Antibiotics
Verified
Journal Article
Open access
PDF file
APANTRIA PAPAZACHARIOU
ANTRIA PAPAZACHARIOU
NTNikolaos-Renatos Tziolos
Nikolaos-Renatos Tziolos
Stamatis KarakonstantisStamatis Karakonstantis
Stamatis Karakonstantis
PIPetros Ioannou
Petros Ioannou
GSGeorge Samonis
George Samonis
DKDiamantis P Kofteridis
Diamantis P Kofteridis
Acinetobacter baumannii has emerged as a pressing challenge in clinical practice, mainly due to the development of resistance to multiple antibiotics, including colistin, one of the last-resort treatments. This review highlights all the possible mechanisms of colistin resistance and the genetic basis contributing to this resistance, such as modifications to lipopolysaccharide or lipid A structures, alterations in outer membrane permeability via porins and heteroresistance. In light of this escalating threat, the review also evaluates available treatment options. The development of new antibiotics (cefiderocol, sulbactam/durlobactam) although not available everywhere, and the use of various combinations and synergistic drug combinations (including two or more of the following: a polymyxin, ampicillin/sulbactam, carbapenems, fosfomycin, tigecycline/minocycline, a rifamycin, and aminoglycosides) are discussed in the context of overcoming colistin resistance of A. baumannii infections. Although most studied combinations are polymyxin-based combinations, non-polymyxin-based combinations have been emerging as promising options. However, clinical data remain limited and continued investigation is essential to determine optimal therapeutic strategies against colistin-resistant A. baumannii.

24 October 2016 in Critical Care
Verified
Journal Article
Open access
PDF file
RBR. M. Bateman
R. M. Bateman
MSM. D. Sharpe
M. D. Sharpe
JJJ. E. Jagger
J. E. Jagger
CEC. G. Ellis
C. G. Ellis
JSJ. Solé-Violán
J. Solé-Violán
EPE Prandi
E Prandi
[This corrects the article DOI: 10.1186/s13054-016-1208-6.].

21 October 2016 in Expert Review of Molecular Diagnostics
Verified
Journal Article
Closed access
NTNikolaos-Renatos Tziolos
Nikolaos-Renatos Tziolos
EGEvangelos J. Giamarellos-Bourboulis
Evangelos J. Giamarellos-Bourboulis
Although the administration of appropriate antimicrobials within the very first hour remains the mainstay of sepsis management, the correct selection of antimicrobials is hampered by the delay of conventional microbiology providing results after at least 48 hours. Methods of rapid detection of pathogens are an approach to overcome these difficulties. Areas covered: This review analyzes the advantages and the disadvantages of these approaches with major emphasis on technologies based on multiplex PCR for the rapid detection of pathogens using whole blood. The most broadly studied platform is SeptFast. Sensitivity ranges between 42% and 73% and specificity between 50% and 97%. The main disadvantages are high cost, the risk of contamination and the lack of information for the presence of resistance genes. A brief review of the use of PCR techniques for the diagnosis of endocarditis and of the recognition of the bacterial proteome for the rapid identification of grown colonies (MALDI-TOF) is also provided. Expert commentary: More randomized clinical trials are necessary to validate the use of molecular techniques for decision-making for patients' outcomes, taking into consideration the cost-benefit for the patient.

1 December 2015 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
NTNikolaos-Renatos Tziolos
Nikolaos-Renatos Tziolos
Anastasia KotanidouAnastasia Kotanidou
Anastasia Kotanidou
SOStylianos E. Orfanos
Stylianos E. Orfanos